The earnings call reflects a robust performance with significant revenue growth and clinical progress, particularly in epilepsy and cardiopulmonary segments. However, supply chain challenges and some transitional issues in neuromodulation pose risks. Overall, the sentiment is positive given the strong financial performance and raised guidance.

Company Guidance -

Q3 2025

During LivaNova's second quarter 2025 earnings call, the company reported a 10% organic revenue growth, with cardiopulmonary segment revenue rising 13% to $199 million. This growth was driven by heart-lung machine sales and oxygenator revenue, both seeing low double-digit increases. The company upgraded its cardiopulmonary revenue growth forecast for the full year to 12%-13%. LivaNova's epilepsy segment grew 6%, with U.S. revenue up 5%, and Europe and Rest of World regions combined seeing a 9% increase. The company raised its epilepsy revenue growth guidance to 4.5%-5.5% for 2025. Additionally, LivaNova highlighted advancements in epilepsy, including promising long-term data from the CORE-VNS study and progress in obstructive sleep apnea with the FDA, reinforcing its commitment to addressing unmet medical needs. The company's full-year guidance was increased, expecting 8%-9% constant currency revenue growth, 9%-10% organic growth, and adjusted EPS between $3.70 and $3.80, reflecting strong operational performance and strategic investments.

Strong Organic Revenue Growth

LivaNova delivered 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance.

Significant Clinical and Regulatory Milestones in Epilepsy

Announced long-term results from the CORE-VNS study showing 80% seizure reduction in focal onset seizures and 95% in focal to bilateral tonic-clonic seizures.

Cardiopulmonary Segment Performance

Cardiopulmonary revenue increased 13% versus Q2 2024, with heart-lung machine revenue and oxygenators both growing in low double digits.

CMS Proposal for VNS Therapy

Initiated the process with CMS for national Medicare coverage for VNS therapy in patients with treatment-resistant depression, supported by strong 24-month outcomes.

Improved Financial Performance

Adjusted operating income grew 13% year-over-year and adjusted free cash flow increased from $53 million to $68 million in the first half of 2025.

Raising 2025 Revenue Guidance

Overall organic growth outlook raised by 200 basis points to between 9% and 10% for the full year 2025.

LivaNova (LIVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LIVN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.93 / -	0.9	―	―	―
Aug 06, 2025	2025 (Q2)	0.87 / 1.05	0.93	12.90% (+0.12)
May 07, 2025	2025 (Q1)	0.76 / 0.88	0.73	20.55% (+0.15)
Feb 25, 2025	2024 (Q4)	0.80 / 0.81	0.87	-6.90% (-0.06)
Oct 30, 2024	2024 (Q3)	0.72 / 0.90	0.73	23.29% (+0.17)
Jul 31, 2024	2024 (Q2)	0.78 / 0.93	0.78	19.23% (+0.15)
May 01, 2024	2024 (Q1)	0.49 / 0.73	0.43	69.77% (+0.30)
Feb 21, 2024	2023 (Q4)	0.77 / 0.87	0.81	7.41% (+0.06)
Nov 01, 2023	2023 (Q3)	0.64 / 0.73	0.58	25.86% (+0.15)
Jul 26, 2023	2023 (Q2)	0.54 / 0.78	0.53	47.17% (+0.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LIVN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$42.61	$47.36	+11.15%
May 07, 2025	$35.16	$43.50	+23.72%
Feb 25, 2025	$49.50	$41.70	-15.76%
Oct 30, 2024	$52.97	$51.34	-3.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does LivaNova PLC (LIVN) report earnings?

LivaNova PLC (LIVN) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is LivaNova PLC (LIVN) earnings time?

LivaNova PLC (LIVN) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LIVN EPS forecast?

LIVN EPS forecast for the fiscal quarter 2025 (Q3) is 0.93.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing